Literature DB >> 21345967

Transcriptional repression of C4 complement by hepatitis C virus proteins.

Arup Banerjee1, Budhaditya Mazumdar, Keith Meyer, Adrian M Di Bisceglie, Ratna B Ray, Ranjit Ray.   

Abstract

The fourth component of human complement (C4) plays an important role in innate immune function. C4 activity has been observed to be significantly lower in patients with chronic hepatitis C virus (HCV) infections, although the mechanism remains unknown. In this study, we have examined the mechanisms of C4 regulation by HCV. Liver biopsy specimens from patients with chronic HCV infections displayed significantly lower C4 mRNA levels than liver tissue samples from patients with unrelated liver disease. Further, C4 mRNA levels of the two isoforms (C4A and C4B) were significantly reduced in hepatocytes transfected with RNA from HCV genotype 1a or 2a. Subsequently, a significant C4 regulatory role of HCV core or NS5A upon C4 promoter activity was observed. HCV core or NS5A transgenic mice displayed a reduction in C4 mRNA. Gamma interferon (IFN-γ)-induced C4 promoter activation was also impaired in the presence of HCV proteins. We further demonstrated that HCV core reduced the expression of upstream stimulating factor 1 (USF-1), a transcription factor important for basal C4 expression. On the other hand, the expression of interferon regulatory factor 1 (IRF-1), which is important for IFN-γ-induced C4 expression, was inhibited by hepatocytes expressing HCV NS5A. These results underscore the roles of HCV proteins in innate immune regulation in establishing a chronic infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21345967      PMCID: PMC3126272          DOI: 10.1128/JVI.02449-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  The role of Sp family members, basic Kruppel-like factor, and E box factors in the basal and IFN-gamma regulated expression of the human complement C4 promoter.

Authors:  D Ulgiati; L S Subrata; L J Abraham
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

2.  Diversity in intrinsic strengths of the human complement system: serum C4 protein concentrations correlate with C4 gene size and polygenic variations, hemolytic activities, and body mass index.

Authors:  Yan Yang; Erwin K Chung; Bi Zhou; Carol A Blanchong; C Yung Yu; George Füst; Margit Kovács; Agnes Vatay; Csaba Szalai; István Karádi; Lilian Varga
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.422

3.  Recognition of the E-C4 element from the C4 complement gene promoter by the upstream stimulatory factor-1 transcription factor.

Authors:  M D Galibert; L Boucontet; C R Goding; T Meo
Journal:  J Immunol       Date:  1997-12-15       Impact factor: 5.422

4.  IFN-gamma up-regulates expression of the complement components C3 and C4 by stabilization of mRNA.

Authors:  T J Mitchell; M Naughton; P Norsworthy; K A Davies; M J Walport; B J Morley
Journal:  J Immunol       Date:  1996-06-01       Impact factor: 5.422

5.  Regulation of the B cell response to T-dependent antigens by classical pathway complement.

Authors:  M B Fischer; M Ma; S Goerg; X Zhou; J Xia; O Finco; S Han; G Kelsoe; R G Howard; T L Rothstein; E Kremmer; F S Rosen; M C Carroll
Journal:  J Immunol       Date:  1996-07-15       Impact factor: 5.422

Review 6.  The complement system in liver diseases.

Authors:  Xuebin Qin; Bin Gao
Journal:  Cell Mol Immunol       Date:  2006-10       Impact factor: 11.530

7.  Chronic hepatitis C, cryoglobulinemia, and cutaneous necrotizing vasculitis. Clinical, pathologic, and immunopathologic study of twelve patients.

Authors:  M S Daoud; R A el-Azhary; L E Gibson; M E Lutz; S Daoud
Journal:  J Am Acad Dermatol       Date:  1996-02       Impact factor: 11.527

8.  Hepatitis C virus core protein is necessary for the maintenance of immortalized human hepatocytes.

Authors:  Arnab Basu; Keith Meyer; Ratna B Ray; Ranjit Ray
Journal:  Virology       Date:  2002-06-20       Impact factor: 3.616

9.  Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model.

Authors:  Carolina Soguero; Myungsoo Joo; Kimberly A Chianese-Bullock; Duong Tony Nguyen; Kenneth Tung; Young S Hahn
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines.

Authors:  Keng-Hsin Lan; Keng-Li Lan; Wei-Ping Lee; Meei-Ling Sheu; Ming-Yuan Chen; Yung-Lu Lee; Sang-Hue Yen; Full-Young Chang; Shou-Dong Lee
Journal:  J Hepatol       Date:  2006-12-14       Impact factor: 25.083

View more
  32 in total

1.  Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus.

Authors:  Young-Chan Kwon; Hangeun Kim; Keith Meyer; Adrian M Di Bisceglie; Ranjit Ray
Journal:  J Immunol       Date:  2016-06-29       Impact factor: 5.422

2.  Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles.

Authors:  Budhaditya Mazumdar; Hangeun Kim; Keith Meyer; Sandip K Bose; Adrian M Di Bisceglie; Ratna B Ray; Michael S Diamond; John P Atkinson; Ranjit Ray
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

3.  Advancing the high throughput identification of liver fibrosis protein signatures using multiplexed ion mobility spectrometry.

Authors:  Erin Shammel Baker; Kristin E Burnum-Johnson; Jon M Jacobs; Deborah L Diamond; Roslyn N Brown; Yehia M Ibrahim; Daniel J Orton; Paul D Piehowski; David E Purdy; Ronald J Moore; William F Danielson; Matthew E Monroe; Kevin L Crowell; Gordon W Slysz; Marina A Gritsenko; John D Sandoval; Brian L Lamarche; Melissa M Matzke; Bobbie-Jo M Webb-Robertson; Brenna C Simons; Brian J McMahon; Renuka Bhattacharya; James D Perkins; Robert L Carithers; Susan Strom; Steven G Self; Michael G Katze; Gordon A Anderson; Richard D Smith
Journal:  Mol Cell Proteomics       Date:  2014-01-08       Impact factor: 5.911

Review 4.  Interactions of viruses and the humoral innate immune response.

Authors:  Bailey E Maloney; Krishani Dinali Perera; Danielle R D Saunders; Naemi Shadipeni; Sherry D Fleming
Journal:  Clin Immunol       Date:  2020-02-04       Impact factor: 3.969

5.  Quantification of C4d deposition and hepatitis C virus RNA in tissue in cases of graft rejection and hepatitis C recurrence after liver transplantation.

Authors:  Alice Tung Wan Song; Evandro Sobroza de Mello; Venâncio Avancini Ferreira Alves; Norma de Paula Cavalheiro; Carlos Eduardo Melo; Patricia Rodrigues Bonazzi; Fatima Mitiko Tengan; Maristela Pinheiro Freire; Antonio Alci Barone; Luiz Augusto Carneiro D'Albuquerque; Edson Abdala
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-02-13       Impact factor: 2.743

6.  Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes.

Authors:  Young-Chan Kwon; Sandip K Bose; Robert Steele; Keith Meyer; Adrian M Di Bisceglie; Ratna B Ray; Ranjit Ray
Journal:  J Virol       Date:  2015-09-09       Impact factor: 5.103

7.  Hepatitis C virus induces epithelial-mesenchymal transition in primary human hepatocytes.

Authors:  Sandip K Bose; Keith Meyer; Adrian M Di Bisceglie; Ratna B Ray; Ranjit Ray
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

8.  Binding of Free and Immune Complex-Associated Hepatitis C Virus to Erythrocytes Is Mediated by the Complement System.

Authors:  Kazi Abdus Salam; Richard Y Wang; Teresa Grandinetti; Valeria De Giorgi; Harvey J Alter; Robert D Allison
Journal:  Hepatology       Date:  2018-11-01       Impact factor: 17.425

9.  Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function.

Authors:  Hangeun Kim; Keith Meyer; Adrian M Di Bisceglie; Ranjit Ray
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

10.  Hepatitis C virus-mediated inhibition of cathepsin S increases invariant-chain expression on hepatocyte surface.

Authors:  Hangeun Kim; Budhaditya Mazumdar; Sandip K Bose; Keith Meyer; Adrian M Di Bisceglie; Daniel F Hoft; Ranjit Ray
Journal:  J Virol       Date:  2012-07-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.